$8.85
1.99% day before yesterday
Nasdaq, Jan 02, 10:00 pm CET
ISIN
CA29286M1059
Symbol
ENGN

EnGene Stock price

$8.85
+0.99 12.60% 1M
+5.11 136.63% 6M
-0.18 1.99% YTD
+1.79 25.35% 1Y
-1.48 14.33% 3Y
-1.01 10.24% 5Y
-1.01 10.24% 10Y
-1.01 10.24% 20Y
Nasdaq, Closing price Fri, Jan 02 2026
-0.18 1.99%
ISIN
CA29286M1059
Symbol
ENGN
Industry

Key metrics

Basic
Market capitalization
$592.8m
Enterprise Value
$414.0m
Net debt
positive
Cash
$201.9m
Shares outstanding
51.1m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
negative
P/B
3.0
Financial Health
Equity Ratio
87.6%
Return on Equity
-20.2%
ROCE
-44.9%
ROIC
-253.7%
Debt/Equity
0.1
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
$-100.7m | $-115.5m
EBIT
$-101.1m | $-116.6m
Net Income
$-94.7m | $-111.5m
Free Cash Flow
$-95.1m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
-83.1% | -86.4%
EBIT
-82.9% | -87.2%
Net Income
23.3% | -102.2%
Free Cash Flow
-162.0%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$-1.9
FCF per Share
$-1.9
Short interest
2.0%
Employees
57
Rev per Employee
$0.0
Show more

Is EnGene a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,082 stocks worldwide.

EnGene Stock Analysis

Unlock Scores for Free

Analyst Opinions

17 Analysts have issued a EnGene forecast:

15x Buy
88%
2x Hold
12%

Analyst Opinions

17 Analysts have issued a EnGene forecast:

Buy
88%
Hold
12%

Financial data from EnGene

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jul '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 27 27
20% 20%
-
- Research and Development Expense 74 74
126% 126%
-
-101 -101
83% 83%
-
- Depreciation and Amortization 0.42 0.42
45% 45%
-
EBIT (Operating Income) EBIT -101 -101
83% 83%
-
Net Profit -95 -95
23% 23%
-

In millions USD.

Don't miss a Thing! We will send you all news about EnGene directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

EnGene Stock News

Neutral
Business Wire
12 days ago
BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, today announced its financial results for the full year ended October 31, 2025, and provided a business update. “We are closing 2025 in a position of strength: enrollment in LEGEND's pivotal cohort is complete and the recent data update from ...
Neutral
Business Wire
about one month ago
BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN or “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, today announced that the U.S. Food and Drug Administration (FDA) has selected detalimogene voraplasmid (also known as detalimogene and previously EG-70) to participate in the Chemistry, Manufacturing, and Controls (CMC) Development and Read...
Neutral
Business Wire
about one month ago
BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN or “enGene”), a clinical-stage, non-viral genetic medicines company, today announced that Alex Nichols, Ph.D., Chief Strategy and Operations Officer, will present at the Piper Sandler 37th Annual Healthcare Conference on Tuesday, December 2, 2025, at 12:10 p.m. ET. A webcast of the presentation can be accessed on the "Events...
More EnGene News

Company Profile

enGene Holdings, Inc. is a clinical-stage biotechnology company, which engages in developing gene therapies. It is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs. The company was founded by Anthony T. Cheung on April 24, 2023 and is headquartered in Saint-Laurent, Canada.

Head office Canada
CEO Ronald Cooper
Employees 57
Founded 2023
Website engene.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today